DataExpo GAKG DeepReport Navigation

Copyright©2015-2024 Acemap, Inc. Shanghai Jiao Tong University. All rights reserved.

沪ICP备18028330号

RS

Rafał Stando

Holy Cross University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Jacek Sadowski

Holy Cross University

Marcin Miszczyk

Medical University of Vienna

Paweł Rajwa

Medical University of Vienna

Bartłomiej Tomasik

Gdańsk Medical University

Gregor Goldner

Comprehensive Cancer Center Vienna

Gabriela Depowska

The Maria Sklodowska-Curie National Research Institute of Oncology

Wojciech Majewski

The Maria Sklodowska-Curie National Research Institute of Oncology

Piotr Kędzierawski

Holy Cross University

Rafał Suwiński

The Maria Sklodowska-Curie National Research Institute of Oncology

Oliwia Masri

The Maria Sklodowska-Curie National Research Institute of Oncology

Cooperative Institutions

The Maria Sklodowska-Curie National Research Institute of Oncology

Centrum Onkologii

Medical University of Vienna

Medical University of Silesia

Comprehensive Cancer Center Vienna

Medical University of Lodz

Vienna General Hospital

Lublin Oncology Center

Jan Kochanowski University

Holy Cross University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Next-Generation Sequencing-Based Analysis of Clinical and Pathological Features of PIK3CA-Mutated Breast Cancer

Diagnostics (2023)

Jolanta Smok-Kalwat Grzegorz Chmielewski Rafał Stando Jacek Sadowski Paweł Macek

Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) is a well-known oncogene with a high prevalence of mutation in breast cancer patients. The effect of the mutation is a deregulation in phosphatidylinositol 3-kinase-related pathways, and, consequently, in unrestricted cell growth and differentiation. With the advent of precision oncology, PIK3CA has emerged as a pivotal treatment target, culminating in the recent approval of alpelisib. Despite years of research on this genetic alteration, certain aspects of its influence on the prognosis of breast cancer remain ambiguous. The purpose of this analysis is to characterize the clinical picture of breast cancer patients with PIK3CA mutation in comparison to the PIK3CA-wild-type group. We examined 103 tumor samples from 100 breast cancer patients using a next-generation sequencing panel. Presence of the mutation was linked to an older age at diagnosis, a lower expression of Ki67 protein, a greater percentage of tumors expressing progesterone receptors, and a notably higher incidence of metastatic disease at presentation. No significant differences were identified in overall and progression-free survival between the two groups. Our findings enhance the understanding of how PIK3CA mutations shape the clinical and prognostic landscape for breast cancer patients.

P110α

10.3390/diagnostics13182887

Cite

Citations (0)

Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study

European Urology Oncology (2023)

Paweł Rajwa Daniele Robesti Michael Chaloupka Fabio Zattoni Alexander Giesen

De novo oligometastatic prostate cancer (omPCa) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and its optimal management remains unknown.

Glutamate carboxypeptidase II

10.1016/j.euo.2023.09.006

Cite

Citations (11)

Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost

Strahlentherapie und Onkologie (2024)

Matthias Moll Łukasz Magrowski Martina Mittlböck Harald Heinzl Christian Kirisits

Abstract Purpose External beam radiotherapy (EBRT) with or without brachytherapy boost (BTB) has not been compared in prospective studies using guideline-recommended radiation dose and recommended androgen-deprivation therapy (ADT). In this multicenter retrospective analysis, we compared modern-day EBRT with BTB in terms of biochemical control (BC) for intermediate-risk (IR) and high-risk (HR) prostate cancer. Methods Patients were treated for primary IR or HR prostate cancer during 1999–2019 at three high-volume centers. Inclusion criteria were prescribed ≥ 76 Gy EQD2 (α/β = 1.5 Gy) for IR and ≥ 78 Gy EQD2 (α/β = 1.5 Gy) for HR as EBRT alone or with BTB. All HR patients received ADT and pelvic irradiation, which were optional in IR cases. BC between therapies was compared in survival analyses. Results Of 2769 initial patients, 1176 met inclusion criteria: 468 HR (260 EBRT, 208 BTB) and 708 IR (539 EBRT, 169 BTB). Median follow-up was 49 and 51 months for HR and IR, respectively. BTB patients with ≥ 113 Gy EQD 2Gy experienced a stable, good BC outcome compared with BTB at lower doses. Patients treated with ≥ 113 Gy EQD 2Gy also experienced significantly improved BC compared with EBRT (10-year BC failure rates after ≥ 113 Gy BTB and EBRT: respectively 20.4 and 41.8% for HR and 7.5 and 20.8% for IR). Conclusions In patients with IR and HR prostate cancer, BTB with ≥ 113 Gy EQD 2Gy offered a BC advantage compared with dose-escalated EBRT and lower BTB doses.

External beam radiotherapy

External beam radiation

10.1007/s00066-024-02245-3

Cite

Citations (1)

Perirectal Spacers in Radiotherapy for Prostate Cancer:A Systematic Review and a Meta-Analysis

Marcin Miszczyk Rafał Stando Giulio Francolini Constantinos Zamboglou Anna Cadenar

10.2139/ssrn.4978625

Cite

Citations (0)

Early lymphocyte levels and low doses radiation exposure of lung predict lymphopenia in radiotherapy for lung cancer

Frontiers in Immunology (2024)

Łukasz Kuncman Matusz Pajdziński Krzysztof Smółka Mateusz Bilski Joanna Socha

Radiation induced lymphopenia (RIL) deteriorate survival and diminishes the benefit of immune checkpoint inhibitors in combined treatment of lung cancer. Given the inconsistent data across various studies on the predictors of RIL, we aim to methodically elucidate these predictors and formulate a practical guide for clinicians.

Radiation Pneumonitis

10.3389/fimmu.2024.1426635

Cite

Citations (1)

A link between seasonality and radiation-related toxicity: The big time or time will tell?

Radiotherapy and Oncology (2021)

Zuzanna Nowicka Robert Bibik Rafał Stando Wojciech Fendler Konrad Stawiski

10.1016/j.radonc.2021.06.010

Cite

Citations (0)

Grade 3 Ependymoma in Adults – a Multi-Institutional Polish Study

Aleksandra Napieralska Elżbieta Nowicka Marcela Krzempek Katarzyna Dyttus‐Cebulok Rafał Stando

Ependymoma

10.2139/ssrn.4873254

Cite

Citations (0)

Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy

Biomedicines (2022)

Łukasz Magrowski Oliwia Masri Jakub Ciepał Gabriela Depowska Zuzanna Nowicka

The prognostic value of inflammatory indices, such as the absolute monocyte count (AMC), has been a subject of interest in recent prostate cancer (PCa) studies, while hemoglobin concentration (HGB) has been recognized as a survival factor in castration-resistant metastatic prostate cancer, but its value remains unclear in localized diseases. The aim of this study was to test the prognostic value of these two simple and inexpensive biomarkers for survival and was based on a cohort of 1016 patients treated with primary radiotherapy and androgen deprivation therapy for localized or locally advanced intermediate- or high-risk PCa. Complete survival data were available for all cases and were based on the National Cancer Registry, with a median observation time of 120 months (Interquartile Range (IQR) 80.9-144.7). Missing blood test data were supplemented using the Nearest Neighbor Imputation, and the Cox Proportional Hazards Regression model was used for analysis. The median age was 68.8 years (IQR 63.3-73.5). The five-year overall survival was 82.8%, and 508 patients were alive at the time of analysis. The median time between blood tests and the first day of radiotherapy was 6 days (IQR 0-19). HGB (p = 0.009) and AMC (p = 0.003) were independent prognostic factors for survival, along with age, Gleason Grade Group, clinical T stage and maximum prostate-specific antigen concentration. This study demonstrates that HGB and AMC can be useful biomarkers for overall survival in patients treated with radiotherapy for localized intermediate- or high-risk PCa.

Interquartile range

10.3390/biomedicines10102514

Cite

Citations (5)

Extremely elevated serum procalcitonin concentration in a patient with stage IV non-small cell lung cancer

Archives of Medical Science (2023)

Rafał Stando Grzegorz Chmielewski

1. Soeroso NN, Tanjung MF, Afiani D, Pradana A, Tarigan SP, Wahyuni AS. Procalcitonin level in non-small cell lung cancer patients among Indonesian population. Open Access Maced J Med Sci 2018; 6: 2123-7. Google Scholar

Procalcitonin

10.5114/aoms/170963

Cite

Citations (0)

2912: Grade 3 ependymoma in adults – a multi-institutional polish study: preliminary results

Radiotherapy and Oncology (2024)

Aleksandra Napieralska Marcela Krzempek Elżbieta Nowicka Katarzyna Dyttus‐Cebulok Rafał Stando

Ependymoma

10.1016/s0167-8140(24)03025-1

Cite

Citations (0)